Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Global Health Ventures to Expand Patent Portfolio

Monday, April 19, 2010

Vancouver, British Columbia -- Global Health Ventures Inc. (OTCBB:GHLV) (the "Company") is pleased to announce that it has filed a new patent under PCT (Patent Corporation Treaty) program on the sublingual drug delivery technology. Under the PCT rule, a patented discovery can be protected in over 80 countries, including China and the United States. The patent, which is entitled "Method of delivering a pharmaceutical composition sublingually", is a new proprietary formulation. The formulation is designed to deliver small molecules such as life style drugs to larger macromolecules rapidly to the blood avoiding gastric and hepatic breakdown.

"As our proprietary technology can deliver many existing drugs via sublingual route, it is critically important to protect such technology under the patent treaties worldwide. The company continues to protect its intellectual property to maintain its leadership in the field of drug delivery," said Dr. Hassan Salari, President & CEO of Global Health.

About Global Health Ventures

Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. X-Excite is presently in clinical trials in Europe.

Notice Regarding Forward Looking Statements

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free